Please login to the form below

Not currently logged in
Email:
Password:

mergers

This page shows the latest mergers news and features for those working in and with pharma, biotech and healthcare.

Allergan investors back AbbVie deal, but is a tax charge looming?

Allergan investors back AbbVie deal, but is a tax charge looming?

Allergan shareholders have voted overwhelmingly to support the $63bn merger with AbbVie, which is still going through antitrust review. ... Allergan chief executive Brent Saunders said the vote showed the ‘overwhelming support’ of shareholders for

Latest news

  • Why Marry? Why Marry?

    Although the textbooks differentiate between mergers, acquisitions. and joint ventures, there is a continuous spectrum of ownership structures, with each deal designed to optimise the risk/return ratio.

  • AbbVie/Allergan's merger faces public opposition AbbVie/Allergan's merger faces public opposition

    all necessary action, includ(ing) blocking the merger, to prevent further harm to consumers,” according to Reuters. ... The merger, noted in the letter, will make AbbVie/Allergan the fourth largest pharmaceutical company.

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    Immatics technology promises to go beyond CAR-T capabilities. Celgene is not slowing down its strategic deals ahead of its merger with Bristol-Myers Squibb, and has strengthened its immunotherapy (IO) ... These candidates are among the most promising in

  • Amgen snaps up Celgene’s Otezla for $13.4bn Amgen snaps up Celgene’s Otezla for $13.4bn

    BMS and Celgene now anticipate their merger closing by the end of 2019, on the earlier side of the most recently updated guidance of end of 2019 or early 2020. ... BMS says that it will use the Otezla cash to pay off its debts faster, and to increase a

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    That would be good news for Bristol-Myers Squibb, which is in the throes of a  $74bn merger with Celgene. ... The merger is intended to counteract a slowdown in its cancer business and create a combined company with an enhanced pipeline and improved

More from news
Approximately 103 fully matching, plus 448 partially matching documents found.

Latest Intelligence

  • A new EU in the making, what lies ahead for pharma? A new EU in the making, what lies ahead for pharma?

    Although she made waves with the rejection of the Alstom Siemens mega merger, she is better placed than other candidates.

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    After a merger with fellow Syncona stablemate Orbit, Soraya has taken on the R&D lead role, charged with developing and eventually gaining approval for its lead investigational gene therapy, GT005 ... She then led the creation of the first integrated

  • M&A drivers in healthcare communications M&A drivers in healthcare communications

    in their chosen niche. These pockets of high-growth, exciting businesses have fuelled company mergers and acquisitions (M&A) in the healthcare communications sector over the last five years, and the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Takhzyro – post-merger Takeda’s debut launch. Takeda’s chief executive Christophe Weber has staked his reputation on the company’s £46bn ($61bn) takeover of Shire, and now needs to demonstrate

  • Deal Watch October 2018

    Mergers and acquisitions - still waiting for the tax-driven wave of activity.

More from intelligence
Approximately 73 fully matching, plus 44 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 51 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics